7 On March 4, the National Health Insurance Administration issued the “Rules for Negotiating Drug Contract Renewal (2023 Edition)” and “Non-Exclusive Drug Bidding Rules (Draft)” to start soliciting opinions from the public. Until 17:00 on July 10th.
Compared with 2022, there is no change in the bidding rules for non-exclusive drugs this year. The main focus is on the slowdown of the decline in drug prices and the negotiation of when drugs will enter the regular list. These aspects have been updated. The 2023 version of the renewal rules has made adjustments in terms of fund expenditure budget, payment standard reduction, and renewal drug price reduction deduction. The reduction of drugs that have been included for more than four consecutive years has been reduced by half compared to the original one. It is basically believed that market expectations will be greatly clarified. , which is a great benefit to the development of domestic innovative drugs. At the same time, for drugs that have been on the market for a long time and whose prices do not need to be adjusted in the short term in the view of the payer, this rule update clearly includes them in the regular medical insurance catalog.
Stimulated by the new regulations on medical insurance negotiations, the innovative drug sector has changed, 7 On the afternoon of April 4, the stock prices of many innovative drug companies skyrocketed. Medical insurance payment is one of the largest payment terminals for pharmaceuticals in China, and among medical insurance policies, medical insurance negotiation and access policies have received the most attention, which directly determine the sales and profits of pharmaceutical companies. Innovative pharmaceutical companies may benefit the most from the announcement of the medical insurance renewal rules. Although the overall downstream demand is currently weak, the long-term positive signal is still a powerful booster. As one of the important pharmaceutical raw materials, the demand for THF is also expected to usher in a boost.
微信扫一扫打赏
